PRAME and CTCFL-reactive TCRs for the treatment of ovarian cancer.
van Amerongen RA, Tuit S, Wouters AK, van de Meent M, Siekman SL, Meeuwsen MH, Wachsmann TLA, Remst DFG, Hagedoorn RS, van der Steen DM, de Ru AH, Verdegaal EME, van Veelen PA, Falkenburg JHF, Heemskerk MHM.
van Amerongen RA, et al. Among authors: heemskerk mhm.
Front Immunol. 2023 Mar 21;14:1121973. doi: 10.3389/fimmu.2023.1121973. eCollection 2023.
Front Immunol. 2023.
PMID: 37026005
Free PMC article.